Health Resource Utilization with Continuous Lenalidomide Treatment (TX) in Elderly Patients (PTS) with newly diagnosed multiple myeloma (NDMM)

e166 PO-148 Health Resource Utilization with Continuous Lenalidomide Treatment (TX) in Elderly Patients (PTS) with newly diagnosed multiple myeloma (NDMM) K. Weisel, D. Vogl, A. Corso, M. Delforge, K. Song, M.A. Dimopoulos, J. Cavenagh, C. Hulin, P. Rodon, B. Arnulf, R. Foa, A. Oriol, S. Guo, J. Catalano, C.J. Gibson, J. Van Oostendorp, A. Ervin-Haynes, T. Facon University Hospital Tuebingen, Tuebingen, Germany; University of Pennsylvania, Philadelphia, Pennsylvania, United States; Policlinico San Matteo Universita Di Pavia, Pavia, Italy; University Hospital Leuven, Leuven, Belgium; Vancouver General Hospital, Vancouver, BC, Canada; National and Kapodistrian University of Athens, Athens, Greece; St Bartholomew’s Hospital, London, United Kingdom; CHU NancyeBrabois, Nancy; Centre Hospitalier de Blois, Blois; Hopital Saint-Louis, Paris, France; Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy; Institut Catala d’Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain; EVIDERA, Lexington, Kentucky, United States; Frankston Hospital, Frankston, Australia; Celgene Corporation, Summit, New Jersey, United States; Service des Maladies du Sang, Hopital Claude Huriez, Lille, France